Literature DB >> 29757904

Early and Late Hepatitis B Reactivation After IFN- or DAA-based Therapy of Recurrent Hepatitis C in Anti-HBc-positive Liver Transplant Recipients.

Alessandra Tucci1, Stefano Rizza2, Donatella Cocchis3, Silvia Martini3, Renato Romagnoli3, Alfredo Marzano2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29757904      PMCID： PMC7228638          DOI： 10.1097/TP.0000000000002241

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  4 in total

1.  Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.

Authors:  N Kawagishi; G Suda; M Onozawa; M Kimura; O Maehara; M Ohara; T Izumi; M Umemura; J Ito; M Nakai; T Sho; M Natsuizaka; K Morikawa; K Ogawa; N Sakamoto
Journal:  J Viral Hepat       Date:  2017-07-29       Impact factor: 3.728

Review 2.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

3.  Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.

Authors:  Julien Vionnet; Manuel Pascual; Barbara Testoni; Christophe Combet; Sébastien Godat; Sandrine Vijgen; Vincent Aubert; Laura Rubbia-Brandt; Fabien Zoulim; Darius Moradpour
Journal:  Hepatology       Date:  2018-01-04       Impact factor: 17.425

4.  Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver.

Authors:  S F Wieland; S Asabe; R E Engle; R H Purcell; F V Chisari
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.